产品名称：MicroVue SC5b-9 Plus EIA* (For MAC assembly, TCC, C5 and terminal pathway activ

For Research Use Only in the United States. Not for use in diagnostic procedures.

The MicroVue SC5b 9 Plus Enzyme Immunoassay measures the amount of the SC5b 9 complex present in human plasma or serum specimens.

The Terminal Complement Complex (TCC, SC5b-9) is generated by the assembly of C5 through C9 as a consequence of activation of the complement system by either the classical, lectin or alternative pathway. The membrane attack complex (MAC), a form of TCC, is a stable complex that mediates the irreversible target cell membrane damage associated with complement activation. Complexes formed in the absence of a target membrane bind to naturally occurring regulatory serum proteins, e.g. the S protein,5-7 at the C5b 7 stage of assembly forming, soluble, non-lytic TCC.

The MicroVue SC5b 9 Plus Enzyme Immunoassay measures the concentration of TCC thereby giving an indication of the status of the terminal complement pathway in the specimen. It uses a monoclonal antibody to the C9 ring of TCC to capture the complex. The trapped TCC is subsequently detected with HRP-conjugated antibodies that bind to antigens of the SC5b 9 complex. This test, which provides a rapid, highly specific and quantitative procedure for measuring TCC levels, is designed for investigations studying the role or status of terminal complement pathway activation in numerous research settings.

References

Müller-Eberhard, H.J. The Membrane Attack Complex, Springer Seminars in Immunopathology, Vol. 7, p.93, 1984.

Lachmann, P.J. and Thompson, R.A. Reactive lysis: The complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J. Exp. Med., Vol. 131, p.643, 1970.

Götze, O., and Müller-Eberhard, H.J. Lysis of erythrocytes by complement in the absence of antibody. J. Exp. Med., Vol. 132, p.898, 1970.

Kolb, W.P., Haxby, J.A., Arroyave, C.M., and Müller-Eberhard, H .J. Molecular analysis of the membrane attack mechanism of complement. J. Exp. Med., Vol. 135, p.549, 1972.

Kolb, W.P., and Müller-Eberhard, H.J. The membrane attack mechanism of complement. Isolation and subunit composition of the C5b-9 complex, J. Exp. Med., Vol. 141, p.724, 1975.

Podack, E.R., Kolb, W.P., and Müller-Eberhard, H.J. The C5b-6 complex: formation, isolation, and inhibition of its activity by lipoprotein and the S-protein of human serum. J. Immunol., Vol. 120, p.1841, 1978.

Podack, E.R. and Müller-Eberhard, H.J. Isolation of human S-protein, of an inhibitor of the membrane attack complex of complement. J. Biol. Chem., Vol. 254, p.9808, 1979.

Sefton, M.V. et al. Using ELISA to evaluate complement activation by reference biomaterials.. J. Mat. Sci, 5:622-627, 1994.

Mold, C. Tamerius, J.D., et al. Complement activation during painful crisis in sickle cell anemia. Clinical Immunology and Immunopathology, 70:3,314-320, 1995.

Rinder, C. et al. Blockade of C5a and SC5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.  J. Clin.Invest, 96:3, 1564-1572, 1995.

Rollins, S. et al. Monoclonal Antibodies directed against C5 and C8 block complement mediated damage of xenogenic cells and organs. Transplantation 60:11, 1284-1292, 1995.

Yeh, G. et al. A soluble chimeric complement inhibitory protein that posses both DAF and Factor I cofactor activities. J. Immuno.158.2872-2881, 1997.